Wasn't aware of this program or this disease. Obviously, I need to do more dd when my only position is being short puts...
++++++++++++++
Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be Presented at American Thoracic Society International Conference
bwire
SAN FRANCISCO (Business Wire) -- Results of a Phase 2a clinical trial evaluating the potential of
NKTR-061 (inhaled amikacin) to treat hospital acquired gram-negative
bacterial pneumonia will be presented at the American Thoracic Society
(ATS) International Conference, May 18 - 23, 2007, in San Francisco.
WHO: Dr. Michael S. Niederman, MD, Chairman, Department of
Medicine, Winthrop-University Hospital, Professor of
Medicine; Vice Chairman, Department of Medicine, SUNY at
Mineoloa.
Dr. Jean Chastre, Professor of Medicine, University of
Paris.
WHAT: Four posters detailing the results of a Phase 2a clinical
trial evaluating the pharmacokinetic, serum and tracheal
aspirate concentration, safety and antibiotic reduction
properties of NKTR-061.
Data will be presented and discussed at this ATS session to
show a reduction in the use of IV antibiotics in
mechanically ventilated patients during treatment of
gram-negative pneumonia with NKTR-061. Further, the data
indicate that the administration of NKTR-061 resulted in
high tracheal aspirate concentrations and high epithelial
lining fluid concentrations of amikacin in gram-negative
pneumonia in intubated mechanically ventilated patients.
Finally, data will be presented indicating that NKTR-061
achieves safe serum concentrations following multiple
dosing in intubated mechanically ventilated patients with
gram-negative pneumonia.
WHEN: Monday, May 21st, 2007, 8:15-11:00 am (PT)
WHERE: The American Thoracic Society (ATS) International Conference
at the San Francisco Marriott Hotel.
ABOUT NKTR-061:
NKTR-061 (inhaled amikacin) is being tested to evaluate the safety
and tolerability of amikacin formulated for inhalation for the
adjunctive treatment of gram-negative pneumonia in ventilated patients
diagnosed with hospital or ventilator associated pneumonia. This new
inhaled antibiotics product candidate leverages Nektar's proprietary
Aerosol Generator that is designed to rapidly deliver aerosolized
antibiotics to the deep lungs, both within and outside of a ventilator
system. The result is a potentially faster-acting, potentially more
effective treatment modality which provides key advantages over
traditional pneumatic or ultra-sonic nebulizer.
ABOUT HOSPITAL-ACQUIRED GRAM-NEGATIVE PNEUMONIA:
Hospital-acquired, gram-negative bacterial pneumonia is a serious
problem which afflicts patients even in the world's most advanced
clinical settings. It is most commonly acquired by patients in
intensive care units who have been put on ventilators for breathing
assistance. Current treatment involves the administration of intensive
antibiotics, supplemental oxygen, and intravenous fluids. Some 25-50%
of those who acquire gram-negative bacterial pneumonia will die from
it.
ABOUT NEKTAR:
... |
